The results of a new clinical study on patented collagen concentrate, were presented today at the American College of Nutrition.
In a randomized, double-blind study of 52 patients, conducted in North America, one group took 40mg patented collagen concentrate and the other a combination of glucosamine (1500mg)+ chondroitin (1200mg). The results show that patented collagen concentrate showed a significant improvement from baseline on all WOMAC, VAS, and Lequesne measurements over the glucosamine + chondroitin combination.
The study, presented at the American College of Nutrition meeting in Arlington, VA on October 3, 2008 by Dr. Bagchi PhD., F.A.C.N. demonstrates the efficacy of patented collagen concentrate in an older arthritic population experiencing joint pain and stiffness in the knees from osteoarthritis. It was observed that both treatments reduced the WOMAC index score which measures the difficulty in physical function, stiffness and pain in the knee. However, treatment with patented collagen concentrate was found to be significantly more effective and reduced the WOMAC score by 33% compared to 14% in glucosamine plus chondroitin treated groups after 90 days. Similar results were obtained for VAS scores. Although both the treatments reduced the VAS score, patented collagen concentrate was found to be most effective with 40% decrease after 90 days of treatment compared to 15.4% in glucosamine plus chondroitin treated groups. The Lequesne’s functional index was used to determine the effect of different treatments on pain during daily activities. Treatment with patented collagen concentrate reduced Lequesne’s functional index score by 20.1% compared to 5.9 % in glucosamine plus chondroitin treated groups. Thus, the patented collagen concentrate treated group showed improvement in daily activities suggesting an improvement in quality of life.
